Cancer News and Research

Latest Cancer News and Research

GENova Biotherapeutics signs LOI with Prime BioResearch

GENova Biotherapeutics Inc. ("GENova") today announced it has signed an LOI with Prime BioResearch, Ltd. ("Prime BioResearch"), another drug acquisition company in the areas of drug development and distribution a business case that will save GENova millions every year in drug development and at the same time more than double GENova's distribution network enabling GENova to potentially exceed its own expectations of reaching 100m+ in revenue in year.

16 Sep 2009

Urgent vaccine requirements for treating epidemic diseases voiced at ECI 2009

As a result of dominant media coverage of new epidemic threats such as swine influenza, other infection risks receive less public attention than they deserve. "We would like to bring to everybody's attention that the infectious diseases with the most severe consequences continue to be old acquaintances such as tuberculosis, HIV/AIDS, malaria and hepatitis C. About six million people worldwide die of these diseases every year," says Professor Dr. Dr. h. c. Stefan H. E. Kaufmann, Director of the Max Planck Institute for Infection Biology in Berlin, at the 2nd European Congress of Immunology ECI 2009.

16 Sep 2009

Comprehensive CT scan gives better indication of significant coronary artery disease

A team of researchers led by Massachusetts General Hospital (MGH) radiologists has developed a computed-tomography-based protocol that identifies both narrowing of coronary arteries and areas of myocardial ischemia - restricted blood flow to heart muscle tissue - giving a better indication of clinically significant coronary artery disease.

16 Sep 2009

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

GENova Biotherapeutics Inc. ("GENova") today announced that it has signed a collaboration agreement with Prime BioResearch, Ltd. ("Prime BioResearch") the agreement is focused on how personalized medicine can be applied to cure cancer.

16 Sep 2009

FDA grants orphan drug status to Advanced Life Sciences' Restanza

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) today announced that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Restanza(TM) (cethromycin), its novel, once daily oral antibiotic, for the prophylactic treatment of plague and tularemia. Both tularemia and plague are classified by the Centers for Disease Control as Category A Bioterrorism Agents, which is the highest priority classification.

16 Sep 2009

Mobetron portable radiation therapy system for breast cancer treatment

One minute of radiation in the operating room (OR) could save the lives of thousands of women being treated for breast cancer in the US today. According to a growing body of research, a 60-second course of radiation therapy delivered during surgery dramatically improves results. But, until recently, logistical and administrative difficulties prevented most patients from receiving this crucial treatment until weeks after their procedures.

16 Sep 2009

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

Bavarian Nordic A/S (OMX: BAVA) announced today that it has signed a contract with the military of an undisclosed EU country for the delivery of a small order for IMVAMUNE(R). The vaccines will be delivered in 2009. The size and value of the contract is undisclosed.

16 Sep 2009

NCI-funded SPORE grant aims to improve kidney cancer treatment

The National Cancer Institute (NCI) has awarded Beth Israel Deaconess Medical Center (BIDMC) an $11.5 million, five-year SPORE grant to focus on cancers of the kidney. Michael Atkins, MD, Deputy Director of BIDMC's Division of Hematology/Oncology, will oversee the grant, which involves collaborations with Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital via the Dana-Farber/Harvard Cancer Center.

16 Sep 2009

New peptide-based cancer vaccine tested in genital cancer patients

Preventive vaccination against infectious diseases has been a major milestone for the health of modern society. The development of therapeutic vaccination against established diseases is much more difficult. For more than 100 years researchers have already tried to develop cancer vaccines and now first promising clinical results raise hopes. A summary of the most attractive new approaches gave Professor Carmen Scheibenbogen, Institut für Medizinische Immunologie, Charité-Universitätsmedizin, at a press conference in Berlin.

16 Sep 2009

Researchers analyze how genome influences human health

Two recent studies by Dartmouth researchers use individual genetic data to reveal the powers and limits of our current understanding of how the genome influences human health and what genes can reveal about the ancestry of the people of New Hampshire.

15 Sep 2009

FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX

BioVex Inc, a biotechnology company developing clinical stage treatments for cancer and the prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has approved the design of a single, pivotal, Phase III clinical trial evaluating its lead product, OncoVEX (GM-CSF), for the first-line treatment of patients with squamous cell cancer of the head and neck.

15 Sep 2009

Zhena's Gypsy Tea launches campaign for breast cancer awareness and prevention

Zhena's Gypsy Tea, the innovative tea company, turns up the heat on the battle against breast cancer with its campaign dedicated to urging awareness, preventing breast cancer and finding a cure. Spearheaded by the slogan; Drink Pink-Think Pink, a 70 cent donation of each sale of a the company's popular PINK SUPERBERRY TEA for Women's Health will go directly to The Breast Cancer Research Foundation(R) (BCRF), in support of finding a cure and funding clinical and genetic research worldwide.

15 Sep 2009

Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

Idera Pharmaceuticals, Inc., a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), today announced that it will discuss its TLR-targeted drug discovery and development programs and provide a general corporate overview at the UBS Global Life Sciences Conference on Monday, September 21, 2009, at 10:30 a.m. EDT at the Grand Hyatt New York Hotel in New York City.

15 Sep 2009

HFSA meeting highlights increased risk of heart failure among childhood cancer survivors

The 13th Annual Scientific Meeting of the Heart Failure Society of America (HFSA) today featured a discussion titled "Cardiovascular Disease in Survivors of Childhood Cancer" presented by Dr. Ming Hui Chen, Director, Stress Echocardiography Program and Program for Cardiac Health in Cancer Survivors, Children's Hospital Boston.

15 Sep 2009

Council briefing series to examine role of public policy in promoting medical innovation

The Council for American Medical Innovation will host a breakfast briefing on Capitol Hill titled "Translational Research - From Bench to Bedside." Health policy experts will explore important changes needed to improve the process of development and approval for safe and effective drugs, biologics, medical devices and diagnostics.

15 Sep 2009

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has signed binding letters of intent with three partners who will exclusively represent BioCryst and its anti-viral peramivir for influenza stockpiling opportunities, as well as for marketing and distribution of peramivir for seasonal influenza upon local regulatory approval, within their territories outside the U.S.

15 Sep 2009

Elekta announces interim results

Demand for Elekta’s clinical solutions, products and services remained strong in the first three months of 2009/10. Order bookings rose by 19 percent in local currency with solid performance in all regions. Net sales grew to SEK 1,440 M and operating result rose to SEK 89 M. Earnings per share improved to SEK 0.62 from SEK 0.02.

From Elekta 15 Sep 2009

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

A study exploring the healing of diabetic skin ulcers using topical oxygen/ozone gas mixtures could not proceed to completion and was now abandoned, according to Ozonics International, LLC, a veteran-owned biotechnology company engaged in the research and development of ozone-based medical therapies.

15 Sep 2009

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

HUYA Bioscience International, the leader in global pharmaceutical co-development with China, today announced a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). HUYA has established a series of strategic partnerships with Chinese science institutes that affords it the opportunity to expand its portfolio of novel biopharmaceutical products.

15 Sep 2009

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

In light of the economy and rising unemployment, people are looking to cut costs wherever they can. As the costs of many surgeries and procedures continue to rise in the US, many are looking for cheaper alternatives abroad. This big business is known as "medical tourism," and often promises healthcare options at a fraction of the cost as in the United States. However, this is one area where bargain shopping is not recommended, counsels Dr. David B. Samadi, Chief of Robotics and Minimally Invasive Surgery at The Mount Sinai Medical Center in New York City.

15 Sep 2009

Cancer News and Research

Latest Cancer News and Research

GENova Biotherapeutics signs LOI with Prime BioResearch

Urgent vaccine requirements for treating epidemic diseases voiced at ECI 2009

Comprehensive CT scan gives better indication of significant coronary artery disease

GENova Biotherapeutics and Prime BioResearch sign collaboration agreement

FDA grants orphan drug status to Advanced Life Sciences' Restanza

Mobetron portable radiation therapy system for breast cancer treatment

Bavarian Nordic to deliver IMVAMUNE(R) vaccines

NCI-funded SPORE grant aims to improve kidney cancer treatment

New peptide-based cancer vaccine tested in genital cancer patients

Researchers analyze how genome influences human health

FDA approves BioVex' design of a Phase III clinical trial to evaluate OncoVEX

Zhena's Gypsy Tea launches campaign for breast cancer awareness and prevention

Idera Pharmaceuticals to discuss TLR-targeted drug discovery and development programs

HFSA meeting highlights increased risk of heart failure among childhood cancer survivors

Council briefing series to examine role of public policy in promoting medical innovation

Biocryst signs agreement with three partners to represent its anti-viral peramivir outside U.S.

Elekta announces interim results

NYSDOH blocks U.S.-Egypt study of ozone-based medical therapies for diabetic skin ulcers

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

Chief of Robotics and Minimally Invasive Surgery shares views on medical tourism

Cancer Research - Second Edition eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in